Arcturus Therapeutics Holdings Inc. (ARCT) conducted its first quarter 2026 earnings call, focusing on financial updates and pipeline developments.
Key Participants
Company Executives
- Neda Safarzadeh – Vice President and Head of IR/PR & Marketing
- Joseph Payne – Founder, President, CEO & Director
- Alan Cohen – Chief Medical Officer
- Dennis M. Mulroy
- Padmanabh Chivukula – Founder, Chief Scientific Officer, COO & Secretary
Conference Call Analysts
- Boran Wang – Guggenheim Securities, LLC, Research Division
- Lili Nsongo – Leerink Partners LLC, Research Division
- Jake Batchelder – William Blair & Company L.L.C., Research Division
- Mayank Mamtani – B. Riley Securities, Inc., Research Division
- Adam Walsh – ROTH Capital Partners, LLC, Research Division
- Angela Qian – Canaccord Genuity Corp., Research Division
- Joohwan Kim – Citigroup Inc., Research Division
- Yale Jen – Laidlaw & Company (UK) Ltd., Research Division
The call operator greeted participants, provided instructions for joining, and confirmed the session is recorded.
Neda Safarzadeh, Vice President and Head of IR/PR & Marketing, opened the discussion. “Good afternoon, and welcome to Arcturus Therapeutics quarterly financial update and pipeline progress call,” she stated.
Joe Payne, President and CEO, leads the presentation alongside Dr. Alan Cohen, Chief Medical Officer, and Dennis Mulroy, Chief Financial Officer. Dr. Patrick Beculolo, Chief Scientific Officer and COO, joins for the Q&A portion.
Safarzadeh highlighted forward-looking statements, noting they fall under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks, uncertainties, and assumptions that may lead actual results to differ materially from projections.
